- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Summer 2015
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) |
Indication | Launch Date |
---|---|---|---|---|---|
Exforge | Novartis | Amlodipine / Valsartan | Lupin Pharmaceuticals | treatment of hypertension and to lower blood pressure | 4/1/2015 |
FemHRT | Warner Chilcott | Norethindrone Acetate / Ethinyl Estradiol | Glenmark Generics | moderate to severe vasomotor symptoms due to menopause and for the prevention of postmenopausal osteoporosis in women at significant risk of osteoporosis | 4/7/2015 |
Generess Fe Tablets | Warner Chilcott | Norethindrone / Ethinyl Estradiol / Ferrous Fumarate | Mylan | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 4/7/2015 |
Exalgo | Mallinckrodt | Hydromorphone Extended-Release Tablets | Perrigo | treatment of chronic pain in opioid-tolerant patients requiring continuous around-the-clock opioid analgesia for an extended amount of time | 4/8/2015 |
Lybrel | Wyeth | Levonorgestrel / Ethinyl Estradiol Tablets USP | Glenmark Generics | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 4/10/2015 |
Kenalog Topical Spray | Sun Pharma | Triamcinolone Acetonide Topical Aerosol | Perrigo | relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses | 4/16/2015 |
Abilify | Otsuka Pharmaceutical | Aripiprazole | Teva Pharmaceutical Industries | treatment of schizophrenia and for the acute treatment of manic and mixed episodes associated with bipolar I disorder | 4/28/2015 |
Seasonale | Teva Women's Health | Levonorgestrel / Ethinyl Estradiol Tablets | Mylan | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 5/5/2015 |
Pulmicort Respules | AstraZeneca | Budesonide Inhalation Suspension | Allergan | maintenance medicine to control and prevent asthma symptoms in children ages 12 months to 8 years | 5/7/2015 |
Lotronex | Prometheus Laboratories | Alosetron Hydrochloride Tablets | Roxane Laboratories | for some women with severe Irritable Bowel Syndrome (IBS) | 5/21/2015 |
DDAVP | Ferring Pharmaceuticals | Desmopressin Acetate Tablets | Glenmark Pharmaceuticals | antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of temporary polyuria and polydipsia following head trauma or surgery in the pituitary region | 5/29/2015 |
Lomedia 24 Fe | Amneal | Norethindrone Acetate / Ethinyl Estradiol / Ferrous Fumarate | Teva | for prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 5/29/2015 |
Actonel | Actavis | Risedronate Sodium Tablets | Teva | help increase bone mass and help reduce the chance of having a spinal or non-spinal fracture (break) and are also used to treat or prevent osteoporosis in either men or women who are taking corticosteroid medicines, and to treat Paget's disease of the bone | 6/1/2015 |
Intuniv | Shire | Guanfacine Hydrochloride Extended-Release Tablets | Mylan | treatment of Attention Deficit Hyperactivity Disorder (ADHD) | 6/2/2015 |
Seasonique | Teva | Levonorgestrel / Ethinyl Estradiol Tablets | Mylan (Famy Care) | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 6/2/2015 |
Intuniv | Shire | Guanfacine Hydrochloride Extended-Release Tablets | Teva | treatment of Attention Deficit Hyperactivity Disorder (ADHD) | 6/2/2015 |
Intuniv | Shire | Guanfacine Hydrochloride Extended-Release Tablets | Sandoz | treatment of Attention Deficit Hyperactivity Disorder (ADHD) | 6/4/2015 |
Dovonex Cream | Leo Pharma | Calcipotriene Cream | Glenmark Pharmaceuticals | treatment for psoriasis | 6/11/2015 |
Seasonale | Teva Women's Health | Levonorgestrel / Ethinyl Estradiol Tablets | Glenmark Pharmaceuticals | prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception | 6/15/2015 |
Copaxone | Teva | Glatiramer Acetate | Sandoz | treatment for relapsing forms of Multiple Sclerosis | 6/18/2015 |
GENERICally Speaking Summer 2015
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.